MitoRx demonstrates mitochondrial therapy holds potential for weight loss

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Mitochondrial-targeted sulfide donor therapy shows metabolic disease promise, reducing weight gain and protecting against muscle loss in mice.

British mitochondrial therapeutics developer MitoRx has published the results of a study that demonstrates the potential of its approach to address obesity. The study showed that one of the company’s mitochondrial-targeted sulfide donor (mtH2SD) drugs significantly slowed the rate of gain in weight of mice on a high-fat diet while also protecting against muscle loss.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE